Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients

NEXT STORY
Nextech AR Signs Virtual Events & Experiences Preferred Channel Partner Deal with Strategic Site Selection
PREV STORY
Digital Therapeutics Market 2021 Size, Share, Growth, Trends, Revenue, Competitive Landscape, Analysis, Forecast Report 2020-2027
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tyme Technologies, Inc. Announces William K. Oh, M.D., Chief of the Division of Hematology and Medical Oncology at Mount Sinai, as Special Advisor for a Phase 2 Trial for Recurrent Prostate Cancer Patients Being Planned at Mount Sinai Hospital

NEW YORK, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (“Tyme” or the ...

author_avatar
NASDAQ Market News

Public Health Laboratory Leaders Honored by APHL

Silver Spring, MD, June 04, 2018 (GLOBE NEWSWIRE) -- The Association of Public Health Laboratories ...

author_avatar
NASDAQ Market News

Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer

author_avatar
NASDAQ Market News